Israel Englander’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,927,557
| Closed | -$41.3M | – | 5960 |
|
|
2026
Q1 | $41.3M | Buy |
1,927,557
+577,638
| +43% | +$8.14M | 0.02% | 969 |
|
|
2025
Q4 | $12.6M | Buy |
1,349,919
+656,599
| +95% | +$5.49M | 0.01% | 2016 |
|
|
2025
Q3 | $4.89M | Sell |
693,320
-514,482
| -43% | -$3.54M | ﹤0.01% | 3179 |
|
|
2025
Q2 | $7.85M | Sell |
1,207,802
-112,293
| -9% | -$772K | ﹤0.01% | 2519 |
|
|
2025
Q1 | $10.5M | Buy |
1,320,095
+1,127,995
| +587% | +$12.2M | 0.01% | 2138 |
|
|
2024
Q4 | $2.43M | Buy |
192,100
+85,606
| +80% | +$1.19M | ﹤0.01% | 3470 |
|
|
2024
Q3 | $1.48M | Sell |
106,494
-61,271
| -37% | -$874K | ﹤0.01% | 3963 |
|
|
2024
Q2 | $2.31M | Buy |
167,765
+138,757
| +478% | +$2.03M | ﹤0.01% | 3414 |
|
|
2024
Q1 | $479K | Buy |
+29,008
| New | +$434K | ﹤0.01% | 4859 |
|
|
2023
Q4 | – | Sell |
-35,786
| Closed | -$439K | – | 6167 |
|
|
2023
Q3 | $439K | Sell |
35,786
-452,338
| -93% | -$5.9M | ﹤0.01% | 4739 |
|
|
2023
Q2 | $5.83M | Buy |
488,124
+268,454
| +122% | +$3.51M | ﹤0.01% | 2529 |
|
|
2023
Q1 | $2.94M | Buy |
+219,670
| New | +$4.29M | ﹤0.01% | 3070 |
|
|
2022
Q3 | – | Sell |
-17,555
| Closed | -$314K | – | 7137 |
|
|
2022
Q2 | $314K | Sell |
17,555
-157,168
| -90% | -$1.62M | ﹤0.01% | 5318 |
|
|
2022
Q1 | $1.73M | Buy |
+174,723
| New | +$2.31M | ﹤0.01% | 4024 |
|
|
2021
Q4 | – | Sell |
-177,945
| Closed | -$4.22M | – | 6901 |
|
|
2021
Q3 | $4.22M | Buy |
+177,945
| New | +$4.26M | ﹤0.01% | 3059 |
|
Other funds holding DAWN
Israel Englander's DAWN Position: Q2 2026 in Review
Israel Englander sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 1,927,557 shares — an estimated $41.3M sold.
Israel Englander first reported a position in DAWN in Q3 2021 and held it in 15 quarters. The position peaked at $41.3M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Israel Englander reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Israel Englander sold 1,927,557 Day One Biopharmaceuticals shares in Q2 2026, an estimated $41.3M.
- Israel Englander first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 15 quarters.
- Israel Englander's Day One Biopharmaceuticals position peaked at $41.3M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.